OverviewSuggest Edit

Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

TypePublic
Founded1979
HQBlue Bell, US
Websiteinovio.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Feb 2019)278
Job Openings18
Revenue (FY, 2018)$30.5 M(-27%)
Share Price (Mar 2019)$3.5 (-2%)

Key People/Management at Inovio Pharmaceuticals

J. Joseph Kim

J. Joseph Kim

CEO
Peter Kies

Peter Kies

CFO
Niranjan Sardesai

Niranjan Sardesai

COO
Mark Bagarazzi

Mark Bagarazzi

Chief Medical Officer
Show more

Inovio Pharmaceuticals Office Locations

Inovio Pharmaceuticals has offices in Blue Bell and San Diego
Blue Bell, US (HQ)
1787 Sentry Pkwy W
San Diego, US
6769 Mesa Ridge Rd
San Diego, US
10480 Wateridge Cir
Show all (3)
Report incorrect company information

Inovio Pharmaceuticals Financials and Metrics

Inovio Pharmaceuticals Revenue

Inovio Pharmaceuticals's revenue was reported to be $30.48 m in FY, 2018
USD

Revenue (FY, 2018)

30.5m

Net income (FY, 2018)

(97.0m)

EBIT (FY, 2018)

(94.1m)

Market capitalization (15-Mar-2019)

343.7m

Closing stock price (15-Mar-2019)

3.5

Cash (31-Dec-2018)

23.7m
Inovio Pharmaceuticals's current market capitalization is $343.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

13.5m10.5m40.6m35.4m42.2m30.5m

Revenue growth, %

(22%)288%(79%)

General and administrative expense

13.6m18.1m23.9m28.3m29.3m

R&D expense

21.4m57.8m88.7m98.6m95.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

9.5m2.4m3.8m1.8m5.2m5.3m24.2m8.1m6.2m12.5m10.4m20.4m2.6m1.5m24.4m2.0m

General and administrative expense

3.3m4.1m4.3m3.2m4.1m4.7m4.4m5.4m5.8m5.8m7.8m6.2m6.3m9.7m7.2m6.8m

R&D expense

5.4m8.2m9.6m7.0m9.4m16.7m16.1m18.2m19.6m27.0m24.5m23.9m25.5m24.6m22.5m21.9m

Operating expense total

8.7m12.4m14.0m10.2m13.5m20.4m20.5m23.6m24.4m32.7m32.3m30.0m31.8m34.3m29.7m28.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

33.7m40.5m57.6m19.1m23.8m23.7m

Accounts Receivable

3.3m2.8m7.3m15.8m6.0m3.3m

Inventories

637.4k798.0k917.3k1.7m

Current Assets

58.7m98.9m171.9m124.6m138.4m87.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

33.1m98.8m88.5m70.7m26.1m70.3m85.5m41.6m28.5m23.3m22.9m23.9m23.3m37.5m15.1m19.4m

Accounts Receivable

10.6m2.7m2.9m1.6m3.3m5.6m11.0m11.2m10.4m17.5m9.9m7.5m6.2m5.1m1.7m2.8m

Current Assets

57.9m121.7m112.9m104.6m87.3m162.1m184.1m160.6m148.0m140.2m106.8m106.9m154.6m123.8m101.8m93.6m

PP&E

2.3m4.5m4.6m5.5m6.5m8.4m8.7m9.0m9.8m15.0m18.5m17.5m16.9m16.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(66.1m)(36.1m)(29.1m)(73.7m)(88.2m)(97.0m)

Depreciation and Amortization

2.1m1.6m1.9m3.1m3.5m5.0m

Inventories

(229.7k)(160.5k)(119.3k)(831.8k)

Accounts Payable

2.2m1.5m6.5m6.4m2.8m550.4k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(50.6m)(10.8m)(21.5m)(28.7m)(10.6m)(16.7m)(11.2m)(8.0m)(26.7m)(47.5m)(23.1m)(32.6m)(66.7m)(32.4m)(39.0m)(64.0m)

Depreciation and Amortization

1.5m721.7k1.1m894.0k1.4m597.4k1.4m2.3m928.6k1.8m3.0m1.3m2.6m3.8m

Accounts Payable

792.1k24.5k(970.9k)4.4m34.0k3.3m(1.6m)(247.0k)2.9m(5.6m)(4.3m)1.1m(6.4m)(9.4m)(4.9m)

Cash From Operating Activities

(16.3m)(13.7m)(21.7m)(21.1m)(5.7m)(15.7m)(29.0m)(47.7m)(15.2m)(31.9m)(49.3m)(12.6m)(31.6m)(56.3m)
USDY, 2018

Revenue/Employee

117.9k

Financial Leverage

1.5 x
Show all financial metrics

Inovio Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

620
Show all operating metrics
Report incorrect company information

Inovio Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Inovio Pharmaceuticals News and Updates

Inovio Pharmaceuticals Reports 2018 Fourth Quarter and Year-End Financial Results

PLYMOUTH MEETING, Pa., March 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA immunotherapies targeted against cancers and infectious diseases, today reported financial results...

Inovio Pharmaceuticals Completes Sale of Additional Convertible Senior Notes

PLYMOUTH MEETING, Pa., March 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the sale of additional 6.50% convertible senior notes due 2024 (the "notes"), bringing the total amount of notes sold to $78.5 million in aggregate principal amount. The...

Inovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

PLYMOUTH MEETING, Pa., Feb. 13, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today its intention to offer, subject to market and other conditions, $65 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering...

Global Wilms Tumor Protein Market: Key Players are GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Sellas Life Sciences Group Ltd, Sumitomo Dainippon Pharma Co Ltd, Vaximm AG

The Global Wilms Tumor Protein Market Report includes a comprehensive analysis of the present market. The report starts with the basic Wilms Tumor Protein Market overview and then goes into each and every detail. Posted via Industry Today. Follow us on Twitter @IndustryToday

Zika Vaccines Market 2019 Is Expected To Witness Three-Fold Growth| Bharat Biotech, Inovio Pharmaceuticals, Cerus Corporation, Sanofi, NewLink Genetics, Immunovaccine, GlaxoSmithKline

Zika Vaccines Market Report aims to define, describe, and forecast on the basis of Market size, share, types, overview, top key vendors. This research report provides analysis and information according to market segments such as geography, technology and application. Posted via Industry Today. Fol…

Ebola Virus Vaccine Market is set to Experience a Revolutionary growth in future | Crucell, Fab Entech, Inovio Pharmaceuticals, Microbiotix

Global Ebola Virus Vaccine study will help you investigate a detailed division of the market by the end user/industry, by best in class product type and by geography with creation, income, utilization, export & import data in these areas, crunching historical data along with primaries and opinio…
Show more
Report incorrect company information

Inovio Pharmaceuticals Frequently Asked Questions

  • When was Inovio Pharmaceuticals founded?

    Inovio Pharmaceuticals was founded in 1979.

  • Who are Inovio Pharmaceuticals key executives?

    Inovio Pharmaceuticals's key executives are J. Joseph Kim, Peter Kies and Niranjan Sardesai.

  • How many employees does Inovio Pharmaceuticals have?

    Inovio Pharmaceuticals has 278 employees.

  • What is Inovio Pharmaceuticals revenue?

    Latest Inovio Pharmaceuticals annual revenue is $30.5 m.

  • What is Inovio Pharmaceuticals revenue per employee?

    Latest Inovio Pharmaceuticals revenue per employee is $109.6 k.

  • Who are Inovio Pharmaceuticals competitors?

    Competitors of Inovio Pharmaceuticals include Reata Pharmaceuticals, Ironwood Pharmaceuticals and Biogen.

  • Where is Inovio Pharmaceuticals headquarters?

    Inovio Pharmaceuticals headquarters is located at 1787 Sentry Pkwy W, Blue Bell.

  • Where are Inovio Pharmaceuticals offices?

    Inovio Pharmaceuticals has offices in Blue Bell and San Diego.

  • How many offices does Inovio Pharmaceuticals have?

    Inovio Pharmaceuticals has 3 offices.